All patients
Age < 65y (younger) Age > 65y Asian type ECOG 0 ECOG 1 Gender, female Gender, male metastasis (brain) NO metastasis (brain) YES metastasis (liver ) smoker (current or former) smoker (Current) smoker (never) stage III (locally advanced) stage IV (metastatic)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
Extensive stage SCLC (Es-SCLC) - 1st Line (L1), durvalumab plus tremelimumab vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CASPIAN (DT ; all population), 2019 0.82 [0.68; 0.99]
0.82 [0.68 ; 0.99 ] CASPIAN (DT ; all population), 2019 1 0% 537 NA not evaluable progression or deaths (PFS)detailed results CASPIAN (DT ; all population), 2019 0.84 [0.70; 1.01]
0.84 [0.70 ; 1.01 ] CASPIAN (DT ; all population), 2019 1 0% 537 NA not evaluable objective responses (ORR)detailed results CASPIAN (DT ; all population), 2019 1.02 [0.72; 1.44]
1.02 [0.72 ; 1.44 ] CASPIAN (DT ; all population), 2019 1 0% 537 NA not evaluable AE (any grade)detailed results CASPIAN (DT ; all population), 2019 4.09 [0.86; 19.46]
4.09 [0.86 ; 19.46 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable AE (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 1.05 [0.74; 1.49]
1.05 [0.74 ; 1.49 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable AE leading to death (grade 5)detailed results CASPIAN (DT ; all population), 2019 1.89 [0.98; 3.64]
1.89 [0.98 ; 3.64 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results CASPIAN (DT ; all population), 2019 2.63 [1.59; 4.36]
2.63 [1.59 ; 4.36 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable STRAE (any grade)detailed results CASPIAN (DT ; all population), 2019 1.45 [0.96; 2.20]
1.45 [0.96 ; 2.20 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable STRAE (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 1.28 [0.83; 1.98]
1.28 [0.83 ; 1.98 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable TRAE (any grade)detailed results CASPIAN (DT ; all population), 2019 1.04 [0.59; 1.84]
1.04 [0.59 ; 1.84 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable TRAE (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 1.15 [0.81; 1.61]
1.15 [0.81 ; 1.61 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable TRAE leading to death (grade 5)detailed results CASPIAN (DT ; all population), 2019 6.24 [1.38; 28.14]
6.24 [1.38 ; 28.14 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable TRAE leading to discontinuation (any grade)detailed results CASPIAN (DT ; all population), 2019 3.75 [1.97; 7.16]
3.75 [1.97 ; 7.16 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable TRAE leading to discontinuation (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 7.10 [2.44; 20.63]
7.10 [2.44 ; 20.63 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 6.06 [0.30; 121.51]
6.06 [0.30 ; 121.51 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable Alopecia TRAE (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 0.25 [0.01; 5.54]
0.25 [0.01 ; 5.54 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable Anaemia TRAE (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 0.68 [0.40; 1.15]
0.68 [0.40 ; 1.15 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable Asthenia TRAE (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 1.51 [0.25; 9.08]
1.51 [0.25 ; 9.08 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable Constipation TRAE (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 2.00 [0.07; 59.99]
2.00 [0.07 ; 59.99 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 2.01 [0.18; 22.28]
2.01 [0.18 ; 22.28 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable Diabetes TRAE (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 4.02 [0.18; 89.63]
4.02 [0.18 ; 89.63 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 3.57 [0.73; 17.33]
3.57 [0.73 ; 17.33 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable Fatigue TRAE (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 0.66 [0.11; 4.01]
0.66 [0.11 ; 4.01 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 0.69 [0.32; 1.48]
0.69 [0.32 ; 1.48 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 2.00 [0.07; 59.99]
2.00 [0.07 ; 59.99 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable Hypophysitis TRAE (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 2.00 [0.07; 59.99]
2.00 [0.07 ; 59.99 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 4.02 [0.18; 89.63]
4.02 [0.18 ; 89.63 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable Increased lipase level TRAE (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 5.08 [0.59; 43.75]
5.08 [0.59 ; 43.75 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable Leucopenia TRAE (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 1.08 [0.51; 2.28]
1.08 [0.51 ; 2.28 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable Myocarditis TRAE (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 2.00 [0.07; 59.99]
2.00 [0.07 ; 59.99 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable Nausea TRAE (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 0.60 [0.14; 2.52]
0.60 [0.14 ; 2.52 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 0.92 [0.64; 1.32]
0.92 [0.64 ; 1.32 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable Paraesthesia TRAE (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 2.00 [0.07; 59.99]
2.00 [0.07 ; 59.99 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 3.02 [0.31; 29.25]
3.02 [0.31 ; 29.25 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable Pruritus TRAE (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 1.00 [0.02; 50.59]
1.00 [0.02 ; 50.59 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable Rash TRAE (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 6.06 [0.30; 121.51]
6.06 [0.30 ; 121.51 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 0.91 [0.50; 1.67]
0.91 [0.50 ; 1.67 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable Thyroiditis TRAE (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 1.00 [0.02; 50.59]
1.00 [0.02 ; 50.59 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable Vomiting TRAE (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 1.00 [0.14; 7.15]
1.00 [0.14 ; 7.15 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable Alopecia AE (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 0.50 [0.04; 5.53]
0.50 [0.04 ; 5.53 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable Anaemia AE (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 0.67 [0.41; 1.07]
0.67 [0.41 ; 1.07 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable Asthenia AE (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 1.68 [0.40; 7.10]
1.68 [0.40 ; 7.10 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable Back pain AE (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 0.50 [0.02; 14.94]
0.50 [0.02 ; 14.94 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable Constipation AE (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 2.00 [0.07; 59.99]
2.00 [0.07 ; 59.99 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable Cough AE (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 2.00 [0.07; 59.99]
2.00 [0.07 ; 59.99 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable Decreased appetite AE (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 2.53 [0.49; 13.15]
2.53 [0.49 ; 13.15 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable Diarrhoea AE (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 2.37 [0.61; 9.26]
2.37 [0.61 ; 9.26 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable Dyspnoea AE (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 1.51 [0.42; 5.42]
1.51 [0.42 ; 5.42 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable Fatigue AE (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 1.00 [0.20; 5.00]
1.00 [0.20 ; 5.00 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable Febrile neutropenia AE (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 0.81 [0.39; 1.69]
0.81 [0.39 ; 1.69 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable Headache AE (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 2.00 [0.07; 59.99]
2.00 [0.07 ; 59.99 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable Hypertension AE (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 7.16 [0.88; 58.62]
7.16 [0.88 ; 58.62 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable Hyperthyroidism AE (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 2.00 [0.07; 59.99]
2.00 [0.07 ; 59.99 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable Increased Lipase Level AE (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 1.51 [0.42; 5.42]
1.51 [0.42 ; 5.42 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable Leucopenia AE (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 0.92 [0.43; 2.01]
0.92 [0.43 ; 2.01 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable Nausea AE (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 1.00 [0.29; 3.50]
1.00 [0.29 ; 3.50 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable Neutropenia AE (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 0.95 [0.66; 1.37]
0.95 [0.66 ; 1.37 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable Pneumonia AE (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 1.00 [0.39; 2.56]
1.00 [0.39 ; 2.56 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable Pruritus AE (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 1.00 [0.02; 50.59]
1.00 [0.02 ; 50.59 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable Pyrexia AE (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 0.50 [0.02; 14.94]
0.50 [0.02 ; 14.94 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable Rash AE (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 6.06 [0.30; 121.51]
6.06 [0.30 ; 121.51 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable Thrombocytopenia AE (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 0.96 [0.53; 1.72]
0.96 [0.53 ; 1.72 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable Vomiting AE (grade 3-4)detailed results CASPIAN (DT ; all population), 2019 1.34 [0.30; 6.04]
1.34 [0.30 ; 6.04 ] CASPIAN (DT ; all population), 2019 1 0% 532 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-11-01 00:57 +01:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 162
- treatments: 634,861
